Pharmacogenetic Testing of Cytochrome P450 System Enzymes in the Therapy of Bipolar Affective Disorder
https://doi.org/10.52667/2712-9179-2022-2-2-90-96
Abstract
Bipolar affective disorder (BPS) is a common and socially significant mental disorder that requires long-term use of psychotropic drugs (PDs). Long-term use of PDs increases the risk of developing adverse drug reactions (ADRs) and/or therapeutic resistance in some patients. This may be due to a genetically determined impairment of PDs metabolism by cytochrome P450 enzymes. Pharmacogenetic testing (PGx) is a method to identify a group of patients with a high risk of developing PDs -induced ADRs. Our experience of using PGx to search for low-functional and non-functional single nucleotide variants (SNVs) / polymorphisms of the CYP1A2, CYP2C8, CYP3A4, CYP3A5 and CYP2D6 genes encoding cytochrome P450 enzymes involved in PDs metabolism demonstrates the importance of this new personalized approach to the choice of PDs and its dosing in patients with pharmacogenetic profile poor metabolizer. The main purpose of the case report is to present the experience of using PGx in the therapy of dipolar affective disorder.
About the Authors
A. K. Khasanova
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Aiperi K. Khasanova
R. F. Nasyrova
V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; Samara State Medical University
Russian Federation
Russian Federation
Regina F. Nasyrova
192019 Saint Petersburg
443099 Samara
References
1. Kato, T. Current understanding of bipolar disorder: toward integration of biological basis and treatment strategies. Psy Clin Neurosciences 2019, 73, 526–540. https://doi.org/10.1111/pcn.12852
2. Shnayder, N.A.; Abdyrakhmanova A.K.; Nasyrova R.F. Phase I of antipsychotics metabolism and its pharmacogenetic testing. Personalized Psychiatry and Neurology 2022, 2, 4-21. https://doi.org/10.52667/2712-9179-2022-2-1-4-21
3. Abdyrakhmanova, A.K.; Shnayder, N.A.; Nasyrova, R.F. A clinical case of late pharmacogenetic diagnosis of adverse reactions during psychopharmacotherapy in a patient with recurrent depressive disorder. Pharmacogenetics and Pharmacogenomics 2021, 2, 21- 23. (In Russ.). https://doi.org/10.37489/2588-0527-2021-2-21-23
4. Dobrodeeva, V.S.; Abdyrahmanova, A.K.; Nasyrova R.F. Personalized approach to antipsychotic-induced weight gain prognosis. Personalized Psychiatry and Neurology 2021, 1, 3-10. https://doi.org/10.52667/2712-9179-2021-1-1-3-10
5. Abdyrakhmanova, A.K.; Shnayder, N.A.; Neznanov, N.G.; Nasyrova R.F. Pharmacogenetics of quetiapine. Personalized Psychiatry and Neurlogyo 2021, 1, 73-83. https://doi.org/10.52667/2712-9179-2021-1-1-73-83
6. Abdyrakhmanova, A.K.; Nasyrova R.F. Pharmacogenetic testing of cytochrome p450 metabolizing enzymes in 28-year-old man with treatment-resistant schizophrenia. Personalized Psychiatry and Neurology 2022, 2, 81-88. https://doi.org/10.52667/2712-9179-2022-2-1-81-88
7. Nasyrova, R.F.; Shnayder, N.A.; Mironov, K.O.; Shipulin, G.A.; Dribnokhodova, O.P.; Golosov, E.A.; Tolmachev, M.Yu; Andreev, B.V.; Kurylev, A.A.; Akhmetova, L.Sh.; Limankin, O.V.; Neznanov, N.G. Pharmacogenetics of schizophrenia in real clinical practice: a clinical case. Neurology, Neuropsychiatry, Psychosomatics 2018, 10, 88–93. https://elibrary.ru/item.asp?id=36547318
8. Shnayder, N. A.; Abdyrakhmanova, A. K.; Nasyrova, R. F. Oxidation of antipsychotics. Encyclopedia 2022, 2, 974–989. https://doi.org/10.3390/encyclopedia2020064
9. Zhuravlev, N.M.; Shnayder, N.A.; Vaiman, E.E.; Abdyrakhmanova, A.K.; Petrova, M.M.; Bochanova, E.N.; Romanova, I.V.; Gavrilyuk, O.A.; Lareva, N.V.; Nasyrova R.F. Interindividual variability of anticonvulsant-induced qt prolongation risk. Personalized Psychiatry and Neurology 2022, 2, 22-45. https://doi.org/10.52667/2712-9179-2022-2-1-23-45
10. Nasyrova, R.F.; Dobrodeeva, V.S.; Scopin, S.D.; Shnayder, N.A.; Neznanov, N.G. Problems and prospects for the implementation of pharmacogenetic testing in real clinical practice in the Russian Federation. Bulletine of Psychiatry, Neurology and Neurosurgery 2020, 3, 6-8. (In Russ.). https://doi.org/10.33920/med-01-2003-01.
11. The Human Protein Atlas. Available online: https://www.proteinatlas.org (accessed on 14 February 2022).
12. Backman, J.T.; Filppula, A.M.; Niemi, M.; Neuvonen, P.J. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev 2016, 68, 168–241. https://doi.org/10.1124/pr.115.011411
13. Zhou, S.F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008, 9(4), 310- 22. doi: 10.2174/138920008784220664.
14. Genesight. Available online: https://genesight.com/product/ (accessed on 11 October 2022).
15. Genecept Assay. Available online: https://ncbi.nlm.nih.gov/gtr/tests/523653.4/ (accessed on 11 October 2022).
Review
For citations:
Khasanova A.K., Nasyrova R.F. Pharmacogenetic Testing of Cytochrome P450 System Enzymes in the Therapy of Bipolar Affective Disorder. Personalized Psychiatry and Neurology. 2022;2(2):90-96. https://doi.org/10.52667/2712-9179-2022-2-2-90-96
Views:
471
Email this article 